Overview
BTIG analysts reviewed the 24‑month data from the VISIONARY trial of Voyxact (sibeprenlimab) in patients with IgA nephropathy (IgAN). The trial demonstrated continued positive changes in estimated glomerular filtration rate (eGFR) through the two‑year mark.
Clinical Efficacy
- The drug achieved an annualized eGFR slope of +0.3 mL/min/1.73 m² per year with a 95 % confidence interval of ‑0.4 to +0.9, satisfying the KDIGO therapeutic goal of limiting progressive kidney function decline to less than 1 mL/min/1.73 m² per year.
- Compared with placebo, Voyxact patients showed an annualized eGFR slope of +0.3 mL/min/1.73 m²/yr versus ‑4.2 mL/min/1.73 m²/yr for placebo, yielding a treatment effect of +4.5 mL/min/1.73 m²/yr (p < 0.0001).
- The least‑squares mean change from baseline was +1.3 mL/min/1.73 m² for Voyxact‑treated patients versus ‑7.9 mL/min/1.73 m² for placebo, a treatment effect of +9.2 mL/min/1.73 m² (p < 0.0001).
Regulatory Milestones
- Following accelerated FDA approval in November 2025, the company initiated a rolling supplemental Biologics License Application (BLA) to expand the indication.
Commercial Performance
- Otsuka reported second‑quarter 2026 Voyxact revenue of approximately $78 million, translating to a run‑rate of about $312 million.
- As of 30 June 2026, more than 2,000 new patients had started treatment since the product’s launch.
- The company projects fiscal‑year 2026 revenue of roughly $375 million, representing the drug’s first full year on the market.
Presentation and Patient Demographics
- The late‑breaking oral presentation of the 24‑month data was delivered at GlomCon in August.
- IgA nephropathy patients typically receive a diagnosis between ages 16 and 35 and require lifelong therapy.